[go: up one dir, main page]

PE20081546A1 - Antagonistas del dr6 - Google Patents

Antagonistas del dr6

Info

Publication number
PE20081546A1
PE20081546A1 PE2008000033A PE2008000033A PE20081546A1 PE 20081546 A1 PE20081546 A1 PE 20081546A1 PE 2008000033 A PE2008000033 A PE 2008000033A PE 2008000033 A PE2008000033 A PE 2008000033A PE 20081546 A1 PE20081546 A1 PE 20081546A1
Authority
PE
Peru
Prior art keywords
humanized
chimeric
antibody
soluble
antagonists
Prior art date
Application number
PE2008000033A
Other languages
English (en)
Inventor
Anatoly Nikolaev
Marc Tessier-Lavigne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20081546A1 publication Critical patent/PE20081546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN ANTAGONISTA DEL RECEPTOR DE MUERTE 6 (DR6) TAL COMO UN ANTICUERPO QUE SE UNE AL DR6 QUIMERICO O HUMANIZADO, UN POLIPEPTIDO DEL DR6 SOLUBLE QUE COMPRENDE LOS AMINOACIDOS 1-354 DE IDENTIFICACION DE SECUENCIA Nº:1 O UN ANTICUERPO QUE SE UNE A LA PROTEINA PRECURSORA AMILOIDE (APP) MONOCLONAL, QUIMERICO O HUMANIZADO. EL POLIPEPTIDO DEL DR6 SOLUBLE COMPRENDE UNA INMUNOADHESINA DEL DR6. DICHOS ANTAGONISTAS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
PE2008000033A 2006-12-22 2008-01-02 Antagonistas del dr6 PE20081546A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87152806P 2006-12-22 2006-12-22
US90084807P 2007-02-12 2007-02-12

Publications (1)

Publication Number Publication Date
PE20081546A1 true PE20081546A1 (es) 2008-12-22

Family

ID=39535220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000033A PE20081546A1 (es) 2006-12-22 2008-01-02 Antagonistas del dr6

Country Status (19)

Country Link
US (1) US20100203044A1 (es)
EP (1) EP2094732A2 (es)
JP (1) JP2010514700A (es)
KR (1) KR20090094854A (es)
AR (1) AR064501A1 (es)
AU (1) AU2007336770A1 (es)
BR (1) BRPI0719459A2 (es)
CA (1) CA2671903A1 (es)
CL (1) CL2007003793A1 (es)
CO (1) CO6210755A2 (es)
MX (1) MX2009006685A (es)
NO (1) NO20092741L (es)
NZ (1) NZ577436A (es)
PE (1) PE20081546A1 (es)
RU (1) RU2009128039A (es)
SG (1) SG177924A1 (es)
TW (1) TW200844113A (es)
WO (1) WO2008080045A2 (es)
ZA (1) ZA201004219B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20120238465A1 (en) * 2011-03-17 2012-09-20 Joseph Audie Drug screening target for alzheimer's disease and method of screening potential drugs
CN102708565A (zh) * 2012-05-07 2012-10-03 深圳市贝尔信智能系统有限公司 一种前景检测的方法、装置和系统
AU2014337504B2 (en) * 2013-10-14 2020-01-30 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
EP3072527B1 (en) 2013-11-20 2022-03-09 National University Corporation Hokkaido University Immunosuppressant
WO2015138698A1 (en) * 2014-03-12 2015-09-17 Temple University-Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
EP3685662B9 (en) 2015-03-16 2023-10-04 Regeneron Pharmaceuticals, Inc. Cell of a rodent exhibiting diminished upper and lower motor neuron function and sensory perception
EP3273982B1 (en) * 2015-03-26 2020-11-18 Suzhou Auzone Biological Technology Co., Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
US20190127476A1 (en) * 2016-05-06 2019-05-02 Abbvie Stemcentrx Llc Novel anti-tnfrsf21 antibodies and methods of use
KR102351126B1 (ko) * 2019-12-03 2022-01-13 재단법인대구경북과학기술원 App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702789A1 (de) * 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
CA2123211C (en) * 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US6013476A (en) * 1997-04-02 2000-01-11 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor TR7
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6949358B1 (en) 1997-06-11 2005-09-27 Human Genome Sciences, Inc. Human tumor necrosis factor receptor TR9
US7378507B2 (en) * 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
US6194151B1 (en) * 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
FR2778858B1 (fr) * 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6916907B1 (en) * 1998-10-23 2005-07-12 Curagen Corporation Nucleic acids encoding osteoprotegern-like proteins and methods of using same
US6423494B1 (en) * 1999-03-25 2002-07-23 Millennium Pharmaceuticals, Inc. DR6 and uses thereof
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
AU2002255881A1 (en) * 2001-03-23 2002-10-08 University Of Utah Research Foundation Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
WO2003039467A2 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
AU2002359459A1 (en) * 2001-12-17 2003-06-30 Eli Lilly And Company Treating b-cell mediated diseases by modulating dr6 activity
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ES2301280A1 (es) * 2005-05-16 2008-06-16 Fina Biotech S.L.U. Metodo para diagnosticar la enfermedad de alzheimer.
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density

Also Published As

Publication number Publication date
RU2009128039A (ru) 2011-01-27
NZ577436A (en) 2012-05-25
CL2007003793A1 (es) 2008-07-25
WO2008080045A3 (en) 2008-09-12
SG177924A1 (en) 2012-02-28
KR20090094854A (ko) 2009-09-08
AR064501A1 (es) 2009-04-08
ZA201004219B (en) 2013-02-27
EP2094732A2 (en) 2009-09-02
NO20092741L (no) 2009-09-21
CA2671903A1 (en) 2008-07-03
CO6210755A2 (es) 2010-10-20
MX2009006685A (es) 2009-07-27
WO2008080045A2 (en) 2008-07-03
TW200844113A (en) 2008-11-16
JP2010514700A (ja) 2010-05-06
US20100203044A1 (en) 2010-08-12
AU2007336770A1 (en) 2008-07-03
BRPI0719459A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
PE20081546A1 (es) Antagonistas del dr6
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
CY1120249T1 (el) Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης
AR093788A1 (es) Inmunoterapia con agentes de enlace
EA202091710A1 (ru) Антитела против cd73 и способы их применения
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
AR110751A1 (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
CR20170539A (es) PROTEINA DE UNIÓN A RGma Y SU USO
EA201491898A1 (ru) Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
CO6612253A2 (es) Agentas y antagonistas fijadores de notch y metodos para el uso de los mismos
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
PE20121361A1 (es) Antagonistas de pcsk9
EA201490677A1 (ru) Связывающие антиген cd27l белки
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
CL2014001074A1 (es) Anticuerpos monoclonales que es anti proteina de union a adn de tar de 43 kda (tdp-43); polinucleotido que lo codifica; composicion farmaceutica que lo contiene; uso del anticuerpo.
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)

Legal Events

Date Code Title Description
FC Refusal